1Kang PM, Landau AJ, Eberhardt RT, et al. Angiotensin Ⅰ receptor antagonists: A new approach to blockade of the renin-angiotensin system[J]. Am Heart J, 1998,127(6): 1388-1401.
2Deshmukh R,Smith A,lilly LS.Hypertension[A] .Lilly LS.Pathophysiology of heart disease[M] .2nd ed. Baltimore: Williams and Wi lkins,1998.267-268.
3Raizada MK, Katovich MJ, Wang HW, et al. Is antisense gene therapy a step in the right direction in the control of hypertension[J]? Am J Physiol, 1999,277(Heart Circ Physiol 7): H423-432.
4Raizade MK, Francis SC, Wang HW, et al. Targeting of the renin-angiotensin system by antisense gene therapy: A possible strategy for the long-term control of hypertensin[J]. J Hypertens, 2000, 18 (2): 353-362.
7Chao J, Chao L. Experimental kallikrein gene therapy in hypertension,cardiovascular and renal disease[J]. Pharmacol Res, 1997,35(3):517-522.
8Gelbane C, Katovich M, Raizada MK. Current perspectives on the use of gene therapy for hypertension[J].Circ Res, 2000,87(10):1118-11122.
9Philips M,Mahuczy-Domiuiak D, Cofley M, et al. Prolonged reduction of hygh blood pressure with an in vivo,nonpathogenic; adeno-associated viral vector delivery of AT RmRNA antisense[J]. Hypertension, 1997,29(2):374-380.
10Dobizynski E, Yoshida H, Chao J, et al. Adenovirus-mediated Kallikrein gene delivery attenuate hypetension and protects against renal injury in deoxycorticoterone-salt rats[J].Immunopharmacology,1999,44(1):57-65.
